{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:09:34Z","timestamp":1778821774393,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Most patients with classical Hodgkin lymphoma (cHL) can achieve long-term survival with frontline combination chemotherapy and radiation therapy, but approximately 10%-30% of patients will develop relapsed\/refractory (R\/R) disease. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) combined with brentuximab vedotin (BV) maintenance therapy improves patient prognosis. However, the management of relapse after ASCT remains a challenge. This report presents a case of a patient with relapsed cHL after ASCT who was successfully treated with targeted therapy combined with two epigenetic modulators. A 26-year-old male patient was diagnosed with stage IIA cHL and received five-line treatment, including ABVD, GemOx-D, anti-PD-1\/PD-L1 monoclonal antibodies, anti-CD47\/PD-L1 bispecific antibodies, and BV combined with ICE, ultimately achieving first complete remission (CR). The patient subsequently underwent peripheral blood ASCT and BV maintenance therapy. However, 16 months post transplantation, disease relapse was detected on follow-up PET\/CT scan. The patient subsequently received 6 cycles of the Ven\u2013Chi\u2013Dec regimen (venetoclax combined with chidamide and decitabine), achieving complete metabolic remission (CMR) with no significant adverse effects. This case report suggests that the Ven\u2013Chi\u2013Dec regimen may be a potential treatment for patients with R\/R cHL after ASCT, although further studies are needed to validate its efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1757010","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:26:44Z","timestamp":1778819204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed\/refractory classical Hodgkin lymphoma: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuelian","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328302c9d8","article-title":"Modern treatment of Hodgkin lymphoma","volume":"15","author":"Bartlett","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: Updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-2-156","article-title":"Salvage therapy in Hodgkin's lymphoma","volume":"12","author":"Byrne","year":"2007","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: A 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213751","article-title":"Navitoclax most promising BH3 mimetic for combination therapy in Hodgkin lymphoma","volume":"23","author":"Langendonk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118979","article-title":"Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin lymphoma","volume":"268","author":"Gamboa-Cede\u00f1o","year":"2021","journal-title":"Life Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B2200016","article-title":"HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression","volume":"23","author":"Luo","year":"2022","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","article-title":"Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000019","article-title":"Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells","volume":"33","author":"Festuccia","year":"2008","journal-title":"Int J Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283245","article-title":"Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax","volume":"109","author":"Zhu","year":"2024","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1475974","article-title":"Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed\/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: A case report and literature review","volume":"15","author":"Jin","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:26:46Z","timestamp":1778819206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1757010"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1757010","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1757010"}}